Sinil Pharmaceutical Co Ltd

Sinil Pharmaceutical Co Ltd maintains a strong liquidity position with a current ratio of 5.63, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to KRW 9,300,882,230, and its free cash flow is KRW 6,596,497,960, suggesting ample liquidity to support operations and potential reinvestment. The debt-to-equity ratio is 0.0, indicating no long-term debt and a conservative capital structure. In terms of profitability, the company's return on equity is 4.94% and return on assets is 4.44%, which are metrics that reflect the efficiency of equity and asset utilization in generating profit. These figures should be compared against the industry median to determine if the company is outperforming or underperforming its peers in terms of profitability and returns. The company's revenue is distributed across five segments: pharmaceuticals, cosmetics, real estate, health functional food, and quasi-pharmaceuticals. The pharmaceutical business is the primary segment, providing a range of treatments for various conditions. The cosmetics and health functional food segments contribute to the company's diversified revenue streams, while the real estate and quasi-pharmaceutical segments add to the overall business mix. The company's growth trajectory is reflected in its financial performance. The operating cash flow is KRW 11,588,758,680, and the capital expenditure is negative, indicating a reduction in capital spending. The outlook for the current fiscal year and the next fiscal year should be analyzed to understand the expected direction of revenue and profitability. The risk assessment for Sinil Pharmaceutical Co Ltd indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure and strong liquidity position reduce the potential for dilution, and the absence of immediate risk flags suggests a stable financial environment. Recent events, such as filings and transcripts, have not indicated any significant changes in the company's financial or operational status. The company's financial snapshot and valuation metrics remain consistent with its historical performance, suggesting a stable and predictable business model.